Trials for GIST Cancer

Current clinical trials for GIST (gastrointestinal stromal tumor) are linkable entries in the list below.

Maps of Trial Locations

When you click this link you will see a world map of GIST cancer trials at the clinicaltrials.gov website. In countries where there are trials you will see a small white block with a black number indicating how many trials are open there. Click the black number to zoom in on the geographic area of your choice. For example, if you click on the USA or Europe, another map will open showing trials in each state or country. Click again on the state or country of your choice to see which trials are available there. NOTE that some trials listed in the table below will NOT appear on this map if GIST is not specifically listed in the trial protocol; for example, trials for any solid tumor may not appear.

Trials by Drug Target

Clinical trials for GIST cancer are listed below according to the class of drug being tested (the target of the drug). For each drug listed under each category, click “Trials at clinicaltrials.gov” to see the open trials relevant to GIST patients at the website www.clinicaltrials.gov.

NOTE: Drugs that are already FDA-approved for other cancers may be prescribed at the discretion of a physician outside of a clinical trial. These drugs are indicated in the list below by “brand name” following the chemical name.

Tyrosine Kinase Inhibitors of KIT and/or PDGFRA:

Sunitinib: Trials at clinicaltrials.gov

Regorafenib: Trials at clinicaltrials.gov

Crenolanib (CP-868,596): Trials at clinicaltrials.gov

PLX9486, PLX3397: Trials at clinicaltrials.gov

DCC-2618: Trials at clinicaltrials.gov

BLU-285: Trials at clinicaltrials.gov

Ponatinib: Trials at clinicaltrials.gov

Cabozantinib: Trials at clinicaltrials.gov

Dasatinib: Trials at clinicaltrials.gov

Immunotherapy:

Nivolumab and Iplimumab: Trials at clinicaltrials.gov

PD-03322991: Trials at clinicaltrials.gov

Intuvax: Trials at clinicaltrials.gov

Pembolizumab: Trials at clinicaltrials.gov

Glutaminase inhibitors:

CB-839: Trials at clinicaltrials.gov

DNA Methyl Transferase inhibitors:

Guadecitabine (SGI-110): Trials at clinicaltrials.gov

Clinical trials targeting KIT

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST), click here to view in clinicaltrials.gov

Phase Ib Study of Sunitinib Alternating With Regorafenib in Patients With Metastatic and/or Unresectable GIST (SURE), click here to view in clinicaltrials.gov

Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation, click here to view in clinical trials.gov

Regorafenib Post-marketing Surveillance in Japan, click here to view in clinicaltrials.gov

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA), click here to view in clinicaltrials.gov

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS), click here to view in clinicaltrials.gov

PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors, click here to view in clinicaltrials.gov

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies, click here to view in clinicaltrials.gov

A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients, click here to view in clinicaltrials.gov

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (STAR-TOR), click here to view link in clinicaltrials.gov

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST), click here to view in clinicaltrials.gov

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST), click here to view in clinicaltrials.gov

Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST), click here to view in clinicaltrials.gov

GIST: Assessment of Tumor Mutations and TKI Plasma Exposure, click here to view in clinicaltrials.gov

Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors, click here to view in clinicaltrials.gov

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST, click here to view in clinicaltrials.gov

Ph II CABOGIST in GIST, click here to view in clinicaltrials.gov

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs, click here to view on clinicaltrials.gov

A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment, click here to view in clinicaltrials.gov

Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy, click here to view in clinicaltrials.gov

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation, click here to view in clinicaltrials.gov

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImaGist), click here to view in clinicaltrials.gov

POETIG Trial – POnatinib After rEsisTance to Imatinib in GIST (POETIG), click here to view in clinicaltrials.gov

Clinical trials targeting PDGFRa:

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST: click here to view in clinicaltrials.gov

Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST), click here to view in clinicaltrials.gov

A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients, click here to view in clinicaltrials.gov

Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors, click here to view in clinicaltrials.gov

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST, click here to view in clinicaltrials.gov

Ph II CABOGIST in GIST, click here to view in clinicaltrials.gov

Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs, click here to view in clinicaltrials.gov

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs, click here to view on clinicaltrials.gov

A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment, click here to view in clinicaltrials.gov

Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy, click here to view in clinicaltrials.gov

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies, click here to view in clinicaltrials.gov

Clinical trials targeting NF-1:

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST): click here to view in clinicaltrials.gov

Clinical trials for young people, Wildtype or SDH-deficient GIST

A Phase II trial of Temodor (Temozolomide)(TMZ) for SDH-deficient GIST patients opened in August 2018. Further info here. Click here to view in clinicaltrials.gov

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor, click here to view in clinicaltrials.gov

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRY), click here to view link in clinicaltrials.gov

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors, click here to view in clinicaltrials.gov

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer, click here to view at clinicaltrials.gov

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor: click here to view in clinicaltrials.gov

Familial Investigations of Childhood Caner Predisposition: click here to view in clinicaltrials.gov

Clinical trials targeting Paragangliomas

131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma, click here to view link on clinicaltrials.gov

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma(FIRSTMAPPP), click here to view in clinicaltrials.gov

Clinical Trials utilizing Immunotherapy:

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery, Click here to view in clinicaltrials.gov

A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors (GIST), click here to view at clinicaltrials.gov

This page is always under revision, and more trials will be added as they are identified.

Current Trials

Trials for GIST Cancer

Maps of Trial Locations

Trials by Drug Target

Tyrosine Kinase Inhibitors of KIT and/or PDGFRA:

Tyrosine Kinase Inhibitors of MEK:

Tyrosine Kinase Inhibitors of CDK:

Tyrosine Kinase Inhibitors of TRK:

Stem cell Kinase Inhibitors:

HSP90 Inhibitors:

Inhibitors of Pathways Downstream of KIT /PDFRa and mTOR inhibitors: